Comerica Securities’s Pacira BioSciences PCRX Stock Holding History

Comerica Securities’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14	Closed	-$541	–	1132
2022 Q4	$541	Buy	+14	New	+$681	﹤0.01%	1415

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Comerica Securities's PCRX Position: Q1 2023 in Review

Comerica Securities sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 14 shares — an estimated $541 sold.

Comerica Securities first reported a position in PCRX in Q4 2022 and held it in 1 quarter. The position peaked at $541 in Q4 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

Comerica Securities reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
Comerica Securities sold 14 Pacira BioSciences shares in Q1 2023, an estimated $541.
Comerica Securities first reported a position in Pacira BioSciences in Q4 2022 and held it in 1 quarter.
Comerica Securities's Pacira BioSciences position peaked at $541 in Q4 2022.
267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on Comerica Securities's 13F filing for Q1 2023, filed 27 Apr 2023.